SLC5A2 and heart failure: Body weight, fasting plasma glucose, plasma insulin, and the insulin/glucagon ratio were lower in chronic dapagliflozin-treated groups compared with vehicle controls; dapagliflozin treatment also increased plasma glucagon, whole-body βOHB turnover, whole-body glucose turnover, circulating βOHB, and circulating acetoacetate levels in heart- failure rats (Figure 7, B–G, and Supplemental Figure 7, A–C), indicative of SGLT2 inhibition.